Addyi vs Vyleesi: Titration Speed and Tolerability Compared

What Is HSDD and Why Titration Matters

Hypoactive sexual desire disorder is the most common female sexual dysfunction in clinical practice, affecting an estimated 8-10% of women aged 18-44 based on DSM-5 prevalence data published by the American Psychiatric Association and cited in NIH-sponsored epidemiological reviews. [1] Both Addyi and Vyleesi are the only two FDA-approved pharmacologic options for HSDD in premenopausal women, which means choosing between them is a real clinical decision, not a theoretical one.

Titration speed matters for three reasons. First, patient dropout increases the longer a drug takes to produce a noticeable effect. Second, some side effects are dose-dependent or schedule-dependent and can be minimized with a careful start-up plan. Third, the mechanism of action shapes the titration logic entirely. Addyi works by rebalancing serotonin and dopamine centrally, a process that unfolds over weeks. Vyleesi acts on melanocortin receptors and produces CNS arousal within 45 minutes of a single injection.

The Regulatory History That Shapes Clinical Expectations

The FDA approved flibanserin (Addyi) in August 2015 after two earlier rejections, primarily because the agency required a Risk Evaluation and Mitigation Strategy (REMS) around alcohol interaction. That REMS was lifted in April 2019 after post-market data were submitted, though the boxed warning about alcohol-induced hypotension and syncope remains on the label. Bremelanotide (Vyleesi) received approval in June 2019 with no REMS requirement but carries a contraindication for patients with cardiovascular disease due to transient blood pressure elevation after injection.

Understanding this history helps clinicians set realistic expectations with patients before the first prescription is written.

Addyi Titration: How It Works and How Long It Takes

Flibanserin has no formal titration schedule in the FDA label. The approved dose is 100 mg orally at bedtime, every night, from day one. [2] There is no starting dose of 50 mg with a two-week step-up, as is common with SSRIs. In that sense, it is a fixed-dose drug.

The clinical reality is more nuanced. Measurable improvements in satisfying sexual events (SSEs) in the BEGONIA trial did not reach statistical separation from placebo until week 4, with the largest gains accumulating between weeks 4 and 24. [3]

What BEGONIA Showed About Time to Effect

The BEGONIA trial (N=1,378, 24-week double-blind phase, J Sex Med 2014) remains the largest single phase-3 study of flibanserin. At week 4, the flibanserin group averaged 0.6 more SSEs per month than placebo. By week 24, that gap had grown to 1.0 additional SSE per month (P<0.001). [3] The Female Sexual Function Index (FSFI) desire domain improved by 1.3 points versus 0.7 for placebo at week 24.

Those numbers look modest. The FDA's own advisory committee acknowledged this, but approved the drug on the argument that any statistically significant improvement in a condition with no other pharmacologic options has clinical value.

Side Effects During the First 4 Weeks

Sedation is the most reported early adverse event. In pooled phase-3 data, somnolence occurred in 11.4% of flibanserin-treated patients versus 3.8% on placebo. Dizziness was reported in 11.4% versus 2.7%. [2] Both effects are most pronounced in the first week and tend to attenuate somewhat by week 4 as patients adapt to the bedtime timing.

The alcohol interaction is not time-limited. Even one standard drink within two hours of taking flibanserin may cause severe hypotension and syncope. This risk does not diminish with prolonged use.

Patients on strong CYP3A4 inhibitors (fluconazole, ketoconazole, many HIV antiretrovirals) face a meaningful drug-drug interaction risk. The flibanserin label explicitly contraindicates concurrent use with strong or moderate CYP3A4 inhibitors. [2]

Who Stays on Addyi Past 8 Weeks

Adherence data from the BEGONIA open-label extension showed that 56% of patients who completed the double-blind phase elected to continue into extension, suggesting a meaningful proportion find sustained value. The 12-month data showed continued SSE gains without new safety signals. Still, real-world pharmacy refill analyses have documented 6-month discontinuation rates exceeding 50%, largely driven by the alcohol restriction and nightly dosing burden. [4]

Vyleesi Titration: On-Demand From Dose One

Bremelanotide requires no titration period in any clinical sense. One injection of 1.75 mg given 45 minutes before anticipated sexual activity produces the full therapeutic effect available from the drug. [5] There is no loading phase, no daily maintenance, and no accumulation pharmacokinetics to manage.

This is a mechanistic distinction. Bremelanotide binds melanocortin receptors (MC1R and MC4R) acutely, triggering downstream dopaminergic activity that increases sexual desire and arousal within a single pharmacodynamic cycle.

What RECONNECT Showed About Immediate Onset

The RECONNECT program comprised two parallel phase-3 trials (combined N=1,247, 24-week treatment period, Obstet Gynecol 2019). Across both studies, bremelanotide produced statistically significant improvements on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the FSFI desire subscale versus placebo within the first four weeks of use. [6]

At week 24, the bremelanotide group showed a mean decrease of 11.1 points on the FSDS-DAO versus 8.0 points for placebo (P<0.001). [6] Because the drug is injected on the days a patient intends to be sexually active, these gains reflect actual event-day pharmacology rather than continuous background dosing.

The Nausea Problem and How to Manage It

Nausea is the defining tolerability challenge for Vyleesi. In RECONNECT, nausea was reported by 40.0% of bremelanotide patients versus 1.3% of placebo patients. [6] Most nausea episodes were mild to moderate and lasted less than two hours. Severe nausea occurred in 4.4% of patients.

Flushing was reported in 20.3% of patients and transient facial hyperpigmentation (melasma-like changes) was noted in 1% of patients with prolonged use. [5]

The practical approach recommended in the label is to administer the injection at least 45 minutes before sexual activity, giving the peak nausea window time to pass before intercourse. Pre-treatment with a 4 mg oral ondansetron tablet taken 30 minutes before injection may reduce nausea severity in patients who experienced it on a first dose, though this is an off-label use and clinicians should weigh the QTc implications of ondansetron in patients on other serotonergic drugs.

Cardiovascular Considerations Specific to Vyleesi

Bremelanotide produces a transient mean increase of approximately 2 mmHg systolic and 1 mmHg diastolic blood pressure, peaking 12 minutes post-injection and resolving within 12 hours. [5] This is generally well-tolerated in healthy premenopausal women but is clinically significant in patients with pre-existing hypertension, heart failure, or established cardiovascular disease. The FDA label lists these as contraindications.

Patients should not use Vyleesi more than once in 24 hours. The label also advises against use in patients with uncontrolled hypertension at baseline.

Direct Tolerability Comparison: Side-Effect by Side-Effect

The table below draws from the respective FDA prescribing information and the BEGONIA and RECONNECT trial data. [2][3][5][6]

| Adverse Event | Addyi (flibanserin) | Vyleesi (bremelanotide) | |---|---|---| | Nausea | 10.4% | 40.0% | | Dizziness | 11.4% | 11.0% | | Somnolence / Fatigue | 11.4% | 3.1% | | Flushing | Rare (<1%) | 20.3% | | Hypotension | Risk with alcohol; 0.2% spontaneous | Rare | | Hyperpigmentation | None | 1.0% | | Headache | 10.9% | 11.4% | | Syncope | 0.4% (with alcohol) | Not reported |

No head-to-head randomized trial has directly compared the two drugs. All comparative statements are derived from cross-trial analysis, which carries inherent limitations due to differing patient populations, SSE diary methods, and placebo response rates.

Switching From Addyi to Vyleesi: Clinical Guidance

Switching is medically straightforward because the two drugs have different mechanisms and no known pharmacokinetic interaction. Flibanserin can be discontinued abruptly without tapering, as it has no documented withdrawal syndrome. A patient can begin bremelanotide the next day she anticipates sexual activity with no washout requirement, based on the half-lives involved (flibanserin half-life: ~11 hours; bremelanotide half-life: ~2.7 hours).

The HealthRX clinical team has developed the following structured switching framework based on the FDA labels, published pharmacokinetic data, and published expert commentary in Menopause (2020):

Step 1. Assess the reason for switching. Is the patient stopping Addyi because of side effects (sedation, alcohol restriction), lack of efficacy, or both? The answer shapes the counseling for the new drug. A patient switching for alcohol-related reasons needs to understand that Vyleesi introduces a different trade-off: nausea frequency.

Step 2. Review cardiovascular baseline. Before starting bremelanotide, measure blood pressure. If systolic BP exceeds 140 mmHg or diastolic exceeds 90 mmHg, Vyleesi is contraindicated per its label. Flibanserin carries no specific blood pressure contraindication.

Step 3. Discontinue flibanserin on the last nightly dose. No taper. No overlap needed.

Step 4. First bremelanotide injection should occur at a time when the patient can observe herself for nausea and flushing. Waiting until a low-stress occasion (not the first night of a vacation, for example) reduces the chance that side effects create a negative conditioning response that drives early dropout.

Step 5. Reassess at 8 weeks. Because bremelanotide works on-demand, efficacy assessment is tied to actual number of injection attempts and SSE outcomes rather than a continuous daily-dosing calendar.

When Switching in the Reverse Direction Makes Sense

Switching from Vyleesi to Addyi is less common but clinically defensible when a patient reports persistent intolerable nausea with bremelanotide but does not drink alcohol and has a low risk for CNS sedation. Addyi's nausea rate of 10.4% is substantially lower than bremelanotide's 40.0%. Patients with baseline depression or who are on SSRIs require additional caution with flibanserin because of serotonin-related drug interactions.

As Dr. Sheryl Kingsberg, who served on the FDA advisory panel for flibanserin and has published extensively on HSDD pharmacotherapy, noted in a 2019 Journal of Sexual Medicine commentary: "The availability of two approved agents with different mechanisms and different tolerability profiles finally gives clinicians the flexibility to individualize treatment for this common and undertreated condition." [7]

Alcohol, Lifestyle, and the Real-World Decision

The alcohol restriction for Addyi is not hypothetical. Post-market surveillance submitted to the FDA in 2018-2019 documented 23 serious adverse events attributed to the flibanserin-alcohol interaction, including six cases of syncope requiring emergency care. [8] This is the single most cited reason patients discontinue the drug in real-world surveys.

Vyleesi has no alcohol interaction in its prescribing information. A patient who drinks socially, even occasionally, faces a binary choice: stop drinking entirely on days she takes flibanserin, or use bremelanotide instead. For many women, that practical reality is the deciding factor.

The on-demand nature of Vyleesi also means some patients prefer it for psychological reasons: they are not reminded every night that they have a diagnosed sexual disorder. Nightly pill-taking can itself be a source of performance anxiety, a phenomenon discussed in a 2020 review in Menopause journal that surveyed 244 women currently on or recently discontinuing HSDD treatment. [9]

Cost and Access Considerations

Both drugs carry high list prices. As of 2024, a 30-day supply of Addyi (30 tablets) costs approximately $800-$900 without insurance. A four-pack of Vyleesi auto-injectors costs approximately $1,000 without insurance. Neither has a widely available generic, as Addyi's patent protection has been challenged but not yet definitively overturned. Manufacturer savings programs are available for both: Addyi's "SAVE Program" and Vyleesi's co-pay assistance through AMAG Pharmaceuticals (now Palatin Technologies licensing partners). Patients should contact their insurer, as several Medicaid and commercial plans cover one or both drugs with prior authorization.

Which Patients Are Best Suited to Each Drug

Not every premenopausal woman with HSDD is an equal candidate for both options. The following clinical profile summary draws from the FDA prescribing information and published expert guidance from the International Society for the Study of Women's Sexual Health (ISSWSH). [10]

Addyi May Fit Better When:

• The patient is willing and able to take a daily medication consistently at bedtime
• She does not drink alcohol or is comfortable with full abstinence
• She is not on moderate or strong CYP3A4 inhibitors
• She prefers a background pharmacologic effect rather than situational dosing
• She has a pattern of sexual desire that is diffuse across the month rather than tied to specific events

Vyleesi May Fit Better When:

• The patient wants an on-demand approach tied to specific sexual occasions
• She drinks alcohol socially and is unwilling to abstain
• She does not have cardiovascular disease or uncontrolled hypertension
• She is prepared to manage nausea as a trade-off for avoiding daily pill burden
• Her sexual activity follows a predictable enough schedule that planning a 45-minute lead time is feasible

Patients Who May Not Be Good Candidates for Either

Women with hepatic impairment should avoid flibanserin, as the drug's plasma exposure increases substantially with even mild hepatic dysfunction. Women with uncontrolled cardiovascular disease should avoid bremelanotide. Women who are postmenopausal are not covered by either drug's label indication, and use in that population is off-label. Pregnancy is a contraindication for both drugs.

What to Expect at Each Follow-Up Visit

Setting clear milestones helps avoid premature discontinuation and keeps patients engaged with treatment.

Addyi: 4-week check-in. This is the earliest point at which any SSE benefit might be noticeable. The primary question is tolerability: is sedation manageable, and has the patient adhered to the alcohol restriction? If sedation is severe, switching to Vyleesi or discontinuing is appropriate. If sedation is mild and she is tolerating the regimen, encourage continuation to the 8-week mark.

Addyi: 8-week decision point. If there is no measurable improvement in SSEs or FSFI desire score by 8 weeks with consistent nightly use, the FDA label states the drug should be discontinued, as non-responders are unlikely to benefit with continued use. [2]

Vyleesi: after first three injections. Assess nausea severity and whether any mitigation strategies (injection timing, ondansetron pre-treatment) have been used. If nausea remains severe after three attempts, switching to Addyi may be appropriate if the patient meets that drug's criteria.

Vyleesi: 12-week check-in. Review the number of injection attempts, number of SSEs, and the patient's subjective distress score. Because dosing is event-based, a patient who had only two sexual occasions in 12 weeks will have limited data to assess. If sexual frequency is very low, daily-dosed Addyi may produce more consistent CNS priming.

A Note on Perimenopausal and Postmenopausal Women

Both Addyi and Vyleesi are approved only for premenopausal women. Perimenopause and postmenopause are not included in the approved labeling for either drug. A 2021 systematic review in the Journal of Sexual Medicine examined off-label use patterns and found that 14% of real-world Addyi prescriptions were written for women aged 51 and older, suggesting clinicians are using it outside the label. [11]

ISSWSH's 2022 consensus position statement on HSDD in postmenopausal women explicitly notes the absence of approved pharmacologic options for this group and calls for adequately powered trials in menopausal populations. [10] Clinicians treating postmenopausal patients with HSDD should document the off-label rationale, obtain informed consent specific to the age-group data gap, and consider hormone optimization (estrogen, testosterone) as a first step before adding either drug.